BackNewAmsterdam Pharma Company NV - Warrants (15/11/2027) Overview

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Cost of Revenue

Cost of Revenue analysis for NAMSW.

Quarterly Cost of Revenue

$500000.00

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$623000.00

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin